Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Human growth hormone lawsuits

Executive Summary

Bio-Technology General asks New Jersey state court March 29 to affirm its position that a non-compete agreement with Serono expires in the middle of the year. Serono maintains that a co-promotion agreement between the two companies for its Saizen hGH brand was improperly terminated and that the non-compete agreement should remain in effect. BTG hopes to launch its own hGH brand July 1; Teva will promote the product. In January, a federal court ruled in favor of BTG in patent litigation against Genentech. Genentech is appealing
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS035815

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel